Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)

NCT06999980 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

494

Enrollment

OTHER

Sponsor class

Conditions

Cutaneous Melanoma
Mucosal Melanoma

Interventions

DRUG: Ipilimumab 3mg/kg and nivolumab 1mg/kg
DRUG: Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg
DRUG: Nivolumab 480mg and relatlimab 160mg
DRUG: Ipilimumab 1mg/kg and nivolumab 3mg/kg
DRUG: Pembrolizumab 200 mg

Sponsor

Melanoma Institute Australia

Collaborators

[object Object]